Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Inclusion Criteria

• Histologically or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation.
• Candidacy to receive treatment with docetaxel. Crossover Inclusion Criteria:
• Evidence of RECIST 1.1 defined disease progression on docetaxel per BICR
• ECOG performance status 0-2

Exclusion Criteria

• Prior treatment with an agent targeting KRAS G12C (e.g., AMG 510, Sotorasib).
• Active brain metastases. Crossover Exclusion Criteria:
• Receipt of any other systemic anti-cancer therapy after last administration of docetaxel on the study.